Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445628 | 1.00 | MAOB (0.84) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL4909255 | 1.00 | MAOB (0.84) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL11458668 | 1.00 | MAOB (0.84) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL4955887 | 0.99 | MAOB (0.82) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL4955899 | 0.99 | MAOB (0.82) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL17340465 | 0.99 | MAOB (0.84) | MAOBHDAC6HSD17B10CYP1A2TRPV1 | |
| SCHEMBL3120231 | 0.91 | MAOB (1.00) | MAOBCYP1A2TRPV1HPGDSMN1; SMN2 | |
| SCHEMBL13271652 | 0.91 | MAOB (1.00) | MAOBCYP1A2TRPV1HPGDSMN1; SMN2 | |
| SCHEMBL3831979 | 0.91 | MAOB (1.00) | MAOBCYP1A2TRPV1HPGDSMN1; SMN2 | |
| SCHEMBL3831982 | 0.91 | MAOB (1.00) | MAOBCYP1A2TRPV1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361685-B2 | Compounds for use in the treatment of skin conditions | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-04-22 | — | — | US | claimed |
| US-20080146987-A1 | TREATMENT OF A SKIN CONDITION USING A PIPERINE-BASED COMPOSITION IN CONJUNCTION WITH IRRADIATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-7361685-B2 | Compounds for use in the treatment of skin conditions | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-04-22 | — | — | US | disclosed |
| US-7122561-B2 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20040254165-A1 | Compounds for use in the treatment of skin conditions | OREGON HEALTH & SCIENCE UNIVERSITY | 2004-12-16 | — | — | US | disclosed |
| US-20040061142-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2004-04-01 | — | — | US | disclosed |
| US-6680391-B2 | PIPERINE AND ANALOGUES OR DERIVATIVES FOR THE TREATMENT OF SKIN CONDITIONS TREATABLE BY STIMULATING MALENOCYTE PROLIFERATION, SUCH AS VITILGO, AND ALSO FOR SKIN CANCER | BTG INTERNATIONAL LIMITED (GB) | 2004-01-20 | — | — | US | disclosed |
| EP-1377571-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SKIN CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20020168369-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2002-11-14 | — | — | US | disclosed |
| WO-2002057260-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SKIN CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-4209446-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF ALKALI METAL HYDROXIDE AND DIPOLAR APROTIC DILUENT | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
| US-4209445-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF QUATERNARY AMMONIUM OR PHOSPHONIUM HYDROXIDE OR CROWN ETHER METAL COMPLEX | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254165-A1 | Compounds for use in the treatment of skin conditions | TYR, MC1R, MITF | MAOB 61/4885HDAC6 807/4885HSD17B10 798/4885 |
| US-20020168369-A1 | Treatment of skin conditions | TYR, MC1R, MITF | MAOB 752/4885HDAC6 1371/4885HSD17B10 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.